U.S., July 26 -- ClinicalTrials.gov registry received information related to the study (NCT07087080) titled 'Plasma Metabolomics as a Tool to Distinguish PET-positive Malignant From PET-positive Benign Nodules' on May 20.
Brief Summary: Positron emission tomography-computed tomography (PET-CT) is an important technique in lung cancer staging, where almost no lung lesion goes undetected. However, PET-CT often fails to discriminate between malignant and non-malignant PET-positive solitary pulmonary nodules (SPNs) with a specificity of only 23%. 40-50% of those patients are advised to repeat their CT after three to six months to follow up on their lesions' progression, delaying a clear and correct cancer diagnosis and subsequent therapy. In m...